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In resource-limited settings, successful HIV treatment scale-up has been tempered by reports of funding shortfalls. We aimed to determine the priorities, including ethical considerations, of decision makers for HIV antiretroviral programs. We conducted qualitative interviews with 12 decision makers, identified using purposive sampling. Respondents engaged in one-on-one, semi-structured interviews. We developed an interview guide to direct questions about key priorities and motivations for decision making about HIV antiretroviral programs. We evaluated textual data from the interviews to identify themes. Among 12 respondents, 10 (83%) lived and worked in South Africa. Respondents came from Western Cape, Gauteng, and KwaZulu-Natal provinces and worked primarily in urban settings. The respondents supported prioritizing individual patients based on treatment adherence, pregnancy status to prevent maternal-to-child HIV transmission and/or orphans, and severity of illness. However, priorities based on severity of illness varied, with first-come/first-serve, prioritization of the most severely ill, and prioritization of the least severely ill discussed. Respondents opposed prioritizing based on patient socioeconomic characteristics. Other priorities included the number of persons receiving treatment; how treated patients are distributed in the population (e.g., urban/rural); and treatment policy (e.g., number of antiretroviral regimens). Motivations included humanitarian concerns; personal responsibility for individual patients; and clinical outcomes (e.g., patient-level morbidity/mortality, saving lives) and/or social outcomes (e.g., restoring patients as functional family members). Decision makers have a wide range of priorities for antiretroviral provision in South Africa, and the motivations underlying these priorities suggest at times conflicting ethical considerations for providing HIV treatment when resources are limited.
Keywords: HIV; HIV/AIDS; antiretroviral therapy; antiretroviral priorities; ethics; South Africa; qualitative interviews Background International initiatives have dramatically increased access to HIV/AIDS treatment in developing countries (WHO, 2008) . However, universal access may remain out of reach. Recent data suggest that in South Africa, a middle-income country where nearly 1 in 5 are HIVinfected, approximately half of those medically eligible for treatment according to 2004 South African guidelines receive it (AIDSinfo; SADOH, 2004) . This figure likely decreases under current national recommendations, which call for earlier antiretroviral therapy (ART) initiation for pregnant women and TB coinfected patients compared with the 2004 guidelines (SADOH, 2010) . Under international guidelines, which recommend earlier treatment initiation for all HIV-infected South Africans, coverage estimates decrease to 37% (AIDSinfo; WHO, 2010) .
While some attribute the treatment gap to inadequate access to care (Bassett et al., 2008; Matovu & Makumbi, 2007) , coverage also has been limited by drug stock-outs, funding constraints, and staff and space shortages, resulting in reported treatment suspensions and waiting lists in some parts of the country (Bateman, 2009; Cullinan, 2009; Thom, 2009; Treatment Action Campaign, 2009 ). For example, from November 2008 to February 2009, Free State budget shortfalls resulted in over 15,000 treatmenteligible individuals on waiting lists and drug shortages among those already on treatment (AIDS Law Project, 2009 ). In July 2009, Edendale Hospital (KwaZulu-Natal province) suspended antiretroviral initiation in over 2000 treatment-eligible patients due to staff and space shortages (AIDS Law Project, 2010) . Threats to donor financing, due to the global economic crisis and changing political commitments, suggest these obstacles could persist (PEPFAR, 2010; UNAIDS, 2009; Zwillich, 2009) .
In settings where barriers to treatment exist, decisions about how to allocate treatment-related resources become inevitable. Challenges exist regarding how treatment should be delivered (e.g., hospital-and/or clinic-based care); who, if anyone, should receive preference (e.g., pregnant women vs. a first-come, first-served approach); and when it should be administered (e.g., receiving antiretrovirals early vs. late in disease progression). Other considerations include unavoidable trade-offs between improving health outcomes for individuals versus the HIV-infected population. In this context, we aimed to assess qualitatively the range of priorities, including ethical considerations, for providing ART to HIV-infected South African adults.
Methods
Below we provide information on the study population, study design, and analysis. Additional details are available in the Supplementary Appendix.
Study population
We used purposive sampling to identify 12 decision makers, defined as stakeholders or policy makers involved in South Africa's HIV treatment scale-up. The study population was limited to individuals working in the health sector with a primary position in a hospital or clinic, government, non-governmental organization, donor agency or foundation, or multi or bilateral organization. Saturation, indicating sample size sufficiency, was achieved since information gained from final interviews reiterated information gained in previous ones (Sandelowski, 1995) .
Study design
We emailed 27 individuals to participate in the study; 12 individuals accepted. Semi-structured, in-depth interviews were conducted face-to-face or via telephone. Interviews occurred in the US (Boston, January to March 2009) and South Africa (Cape Town, Durban, and Johannesburg, February to March 2009). Participants gave verbal informed consent prior to the interview and received no compensation. Human subjects approval was obtained from Harvard University (Cambridge, USA), University of Cape Town (Cape Town, South Africa), and the Western Cape provincial government (Cape Town, South Africa).
We developed an interview guide to shape the interview process, facilitate obtaining relevant information, and ensure key respondent priorities and other contextual factors important for antiretroviral provision in South Africa were explored. Questions and probes focused on priorities for treatment provision, how respondents might set these priorities, points of conflict between or among priorities, and motivations underlying participant responses. Pretest interviews were conducted to ensure general concepts were included, to verify questions and probes were understandable, and to assess question flow and focus . All interviews were conducted by the same facilitator and digitally recorded and transcribed for analysis.
Analysis
Textual data were assessed iteratively in three main stages based on a modified grounded theory approach and thematic content analysis . In Stage 1, data were read and re-read for general impressions. The data were then coded inductively (i.e., during or after data collection) by identified concepts/themes with data sub-classification occurring as necessary. Codes were both preset (i.e., defined before working with the textual data but during or after interviews took place) to reflect our research question and emergent (i.e., defined after working with the data). In Stage 2, we categorized coded data and populated categories with the data in the form of respondent quotations. In Stage 3, we performed axial coding by organizing the categories to evaluate similarities and differences both within and across the respondents. Patterns within and across categories were then identified and interpreted. NVivo8 software (QSR International Pty Ltd) was used to both code and analyze the data.
Results
Below we present results on respondent characteristics, considerations for antiretroviral provision, and underlying motivations and ethical considerations. Additional results are available in the Supplementary Appendix.
Respondent characteristics
Among 12 respondents, all self-identified as health sector decision makers. Respondents came from Western Cape, KwaZulu-Natal, and Gauteng provinces Respondents were not posed direct questions regarding the urban representation of patients for whom they were responsible. However, 8 of 12 respondents provided this information during the interview. c and three-quarters represented patients from rural settings. Table 1 shows additional respondent characteristics.
Considerations for antiretroviral provision Treatment priorities
Respondents discussed treatment priorities, defined as areas in which to improve antiretroviral provision, in terms of both patient and population concerns ( Table  2) . Priorities reflecting patient concerns referred to different patient behaviors serving as criteria for an individual to receive treatment or different patient subgroups to whom treatment could be provided preferentially. Patient concerns discussed included individual patient responsibility (e.g., targeting treatment toward patients demonstrating readiness for or adherence to treatment), maintaining South Africa's social fabric (e.g., targeting treatment toward pregnant women in order to prevent orphans), and vulnerable populations (e.g., targeting treatment toward patients based on severity of illness).
An individual's severity of illness served as a main priority for providing ART in varying ways. For example, a provincial government health worker from Western Cape supported treating individuals firstcome, first-served: I would be very much inclined to continue the firstcome, first-served system. If someone takes the trouble to present themselves, I would be very loathe to turn them away and say, 'No, we can't*we don't want you. We want the person five behind you in the queue.'
In contrast, a physician-scientist from KwaZulu-Natal favored treating critically ill individuals before non-critically ill individuals:
It's the one who is sickest and in front of you that will get the care. And it's bush medicine but that's how it has been even in the most sophisticated hospital.
Finally, a public sector physician from Gauteng province preferred prioritizing treatment of asymptomatic before symptomatic individuals:
To treat a healthy person, allowing them to live longer means that they don't get sick. . . ..[T]hey come in later and later, and they come in very sick. And then you chew up hospitalization resources and healthcare worker resources.
However, some favoring treatment provision to asymptomatic individuals before symptomatic individuals did so in the context of increased access to care to improve patient health outcomes more generally.
Priorities reflecting population concerns referred to broader systems-level approaches toward and aggregate health outcomes related to treatment provision. Respondents discussed antiretroviral coverage (e.g., the number receiving ART or the fraction receiving ART among those eligible to receive it [SADOH, 2004] ); treatment delivery (e.g., point of care, location of care, provider type); integration of ART delivery across diseases (e.g., tuberculosis); and antiretroviral treatment and management policy. They generally supported efforts to increase the number of individuals receiving ART and to change treatment management for stable patients from a vertical approach (via Table 2 . Description of selected priorities for making treatment decisions in South Africa. a
Level of concern
Priority Sample quotations
Patient Adherence
If somebody is really perceived to be an adherence risk, doctors say, 'Well hold on. Maybe, you know, this person may not necessarily just get this drug.' They may need to either work at it*or if I had to choose I might choose somebody who appears to be more reliable.
Children/ orphans . . .
[T]he orphan problem is just a huge, huge problem and getting worse all the time. If you can keep mothers alive to keep their children alive, you solve a lot of downstream problems.
Population
Coverage Success is measured by numbers of people on antiretrovirals who are going back to their lives. And that's the bottom line.
Access
Because we say that we want more people to get onto treatment. But health facilities are 400 or 500 kilometers away from where people live. . . . And that accessibility is the most important. Just bring the treatment closer to the people, whether that means you put it in a van or all primary healthcare clinics are accredited as ARV clinics.
Integration
The intersection of the TB and HIV epidemic where you basically have two different silos providing care is a big operational issue that needs to be addressed in order for people to get one-stop shopping in terms of their health care needs. a Sample quotations regarding additional priorities for antiretroviral provision are presented in the main text.
AIDS Care 781 doctors in hospitals, with therapy delivered separately from treatment for other diseases) to an integrated approach (via nurses in a primary health care clinic, with therapy integrated into management of other diseases). They also favored improved treatment accessibility, typically by providing treatment and care in facilities closer to patients. However, they disagreed regarding the intensity of treatment (e.g., number of antiretroviral regimens, types of drugs making up the regimens, labs for routine follow-up) that should be standard of care in South Africa. For example, some supported a less restrictive policy:
We said two treatment regimens to begin. Maybe we haven't always communicated it well to government. It was never a concept of we would stick with two regimens. That is just not okay. (female physicianscientist, Western Cape)
In contrast, others favored more restrictive treatment policies:
In Other criteria, such as clinical status, were considered more objective. Additional areas in which respondents believed treatment prioritization decisions should not be based included treatment-induced behavior change (i.e., disinhibition) and individualor population-level drug resistance concerns.
Barriers to and financing for treatment provision
To put findings regarding treatment priorities into context, we assessed barriers to treatment provision. In contrast, a non-governmental organization worker noted the need for donor or other external support:
If those [donor] funds were pulled out, it would just come to a grinding halt. The whole HIV program would collapse. In fact the health system of South Africa would collapse.
However, those who believed the South African government should fully financially support ART provision offered few concrete mechanisms for generating additional government funds. While most respondents cited funding, whether government-or donor-supported, as an underlying obstacle to treatment provision, the majority indicated funding resources were not limited since alternative funding sources could always be found. A provincial government health worker noted:
Money can be conjured out of nowhere . . . That's not the rate-limiting factor.
Most of these respondents believed that treatmentrelated constraints generally were temporary and surmountable given resource re-allocation, changes in management and spending practices, and/or political will. However, respondents who did raise concerns about funding stability (predominantly in the context of the global economic crisis) believed that funding constraints would exist permanently. This concern was discussed in terms of patients needing 782 A.D. Kimmel et al. lifelong treatment and that treatment need in South Africa would increase over time.
Underlying motivations and ethical considerations
Motivations underlying respondent priorities for providing treatment broadly fell into two areas Á humanitarian concerns and feelings of responsibility. For some, easing patient suffering or improving quality of life motivated underlying priorities for treatment provision. Additional humanitarian concerns included social welfare:
Part of our legacy is of an extremely brutal society, and it's from a political history of apartheid with communities that have been shattered and a lot of crime. And there's a sense within communities that they've never had a government that really cares for them and nurtures a sense of caring for one another in the society. And that is the core to a healthy society, I think. HIV is an opportunity show that. (public sector physician, Western Cape)
For others, feelings of responsibility toward individual patients and providing them the best possible care motivated their treatment-related priorities. One individual remarked:
You know, for me it's just 'First do no harm.' I think that's the only thing that really drives me. (bilateral agency representative) Given resource constraints, many aimed to provide ART fairly and supported using clinical status to triage patients:
Fairness is just equal opportunity... And fair for me means everybody who qualifies will be put on and I will not be expected to sway from this outside sound clinical judgment. (non-governmental organization worker, Gauteng)
Respondents were also concerned with improving individual clinical outcomes (e.g., patient morbidity and mortality), individual social outcomes (e.g., patient restored as a functional member of the family), and population clinical outcomes (e.g., saving the most lives).
In evaluating these motivations, we found that respondent beliefs reflected different ethical considerations. Considerations ranged from maximizing health outcomes (e.g., by prioritizing treatment for healthier HIV-infected individuals) to providing equality of opportunity for health care (e.g., adhering to objective criteria for treatment initiation) to prioritizing vulnerable populations (e.g., symptomatic or critically ill individuals). However, supplying treatment preferentially to other populations historically considered vulnerable, such as the poor or less educated, was not supported.
We also found that some respondents exhibited internally conflicting beliefs when discussing how they might determine priorities for antiretroviral provision. For example, some discussed treating symptomatic ahead of asymptomatic HIV-infected individuals, and vice versa. One private hospital worker noted:
Part of my job is to try and cut through those rationing things and say to the healthcare worker, 'No, sorry. This patient's an emergency. You have to see him irrespective of the conditions.' Later in the interview, when queried about prioritizing patients based on clinical status, the same respondent stated:
I would use the [antiretroviral] drugs to treat the healthiest population, because that's going to create the most benefit.
Similarly, a provincial government worker said:
Clinical need is obvious. The sicker person should get first. But then that's also a gray area because at some point you might decide the unsalvageable person shouldn't get, you know.
Finally, respondents raised issues regarding individual patient responsibility (e.g., treatment adherence) and equity, including antiretroviral coverage and other distributive issues that would improve treatment access.
Discussion
Our study suggests that HIV treatment decision makers have wide-ranging priorities, including individual patient well-being and broader population outcomes. However, the motivations underlying these priorities indicate at times conflicting ethical considerations for providing HIV treatment when resources are limited.
These findings occur when the HIV/AIDS community may face a crossroads. While international guidelines now recommend earlier treatment initiation and consideration of 3rd-line regimens (WHO, 2009 , WHO, 2010 , evolving political priorities and the consequences of a global economic downturn jeopardize future HIV-related financial commitments (PEP-FAR, 2010; Zwillich, 2009 ). In South Africa, national guidelines recommend later treatment initiation; however, earlier ART initiation was recently recommended for pregnant women and HIV/TB-co-infected patients AIDS Care 783 and the possibility of 3rd-line regimens also has been introduced (SADOH, 2010). Although South Africa's publically funded HIV/AIDS conditional grant is projected to increase over time, external donor funding levels remain in question (PEPFAR, 2010; SADOH, 2010; The Global Fund, 2010) .
Our study had some limitations. First, we confined the sample to 12 health sector decision makers since funding, time, and accessibility constraints limited our ability to extend our sampling. This may have excluded information had our sample included respondents from other sectors and/or representative South African patients. However, we found that information gained in the final interviews was repetitive of that gained in previous ones, indicating saturation among health sector respondents had been achieved (Sandelowski, 1995) . Additionally, most respondents believed that, through their work, they represented additional sectors, including education, business, and law. Second, individuals involved in pre-test interviews did not come from the same sample population as the respondents. However, pretest interviews informed revisions to the interview guide that allowed collecting richer and more meaningful data. Third, in our sampling, we may have over-represented the better-resourced Western Cape province relative to other less-resourced provinces. However, since we aimed to determine the range of priorities for antiretroviral provision, versus their relative frequency, we do not believe our results would have changed. Finally, we were not able to collect conclusive information regarding respondents' support of different ethical considerations. Given interview time constraints, we limited main questions to those that would assist in determining the range of priorities relevant for HIV treatment provision in South Africa and posed probes on ethical considerations only as time permitted. We believe the ethical insights provided enough information from which to identify a potential range of ethical considerations supported by respondents and the ethical conflicts they might experience. However, additional time would have allowed deeper delving into these issues.
Our findings raise a number of implications and areas for future work. For example, differing motivations and underlying ethical considerations may lead to disagreements about priority setting. Research is warranted regarding whether these disagreements exist; if they differ based on stakeholder role, training, or other dimension; and how disagreements might be resolved. Moreover, while disagreements may arise in a research context, further work is required to determine if they occur in practice.
In a climate of uncertain HIV-related funding but a growing number of HIV-infected individuals pre-senting for and remaining in care, decision-makers face difficult policy choices. Understanding HIV treatment priorities and the ethical considerations underlying them can assist in providing treatment efficiently, effectively, and within a belief system reflecting that of local stakeholders.
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The study population was obtained using purposive sampling strategies, relying on maximum variation and snowball sampling methods . Maximum variation sampling was chosen to capture the heterogeneity and range of setting variation inherent in South Africa's antiretroviral scale-up effort, while snowball sampling was chosen to help identify and provide access to additional respondents .
The study's main inclusion criterion was an individual's status as a decision maker in South Africa's HIV treatment scale-up efforts. Motivating this criterion, along with our definition of a decision maker, was an assumption that decision making can take place directly (i.e., primary involvement in making decisions) or indirectly (i.e., implementing or informing decisions) and that it can occur at the individual, organizational, or governmental levels. Exclusion criteria included: work only at the patient level (e.g., a health care professional who is not in a formal position of leadership within an organization); non-English speaking; education less than 9 th -grade level; and age less than 18 years.
Potential respondents were classified as: (a) having direct versus indirect contact with HIV-infected individuals, and (b) whether or not South Africa serves as the respondent's primary area of focus. This sampling framework was intended not only to provide further structure during recruitment, but also to ensure that we recruited respondents who had wide-ranging experiences across occupations and settings within the health sector. The study sample could include, but was not required to include, people living with HIV/AIDS; however, we did not collect any information on HIV status.
Respondents were identified in phases. In Phase I, respondents were identified via social networking and publicly available information. Social networking occurred via contacts from professional colleagues and conference attendance (e.g., XVII International AIDS Conference). Additional respondent sources included conference rosters (e.g., HIV/AIDS Implementers' Meetings, PEPFAR in South Africa Annual Partners Meeting), members of the South African National AIDS Council, and members of a Task Team involved in development of the South African government's HIV/AIDS National Strategic Plan (South African National AIDS Council, 2007) . Phase II respondents were identified after initial data collection by respondents from Phase I via snowballing (described above). It was anticipated that the sampling described above would result in 10Á20 respondents.
Study design
Respondents engaged in one-on-one oral interviews. Twenty-seven individuals were identified and invited via email to participate in the study, with 12 individuals accepting the invitation to participate. Potential subjects were contacted in person, via phone, or via email and invited to participate in a 1-hour interview; invitations described the nature of the research (i.e., for doctoral research) as well as purpose of the interview (i.e., to understand the range of treatment priorities for antiretroviral therapy provision in South Africa). The interviewer engaged in a semi-structured, in-depth interview either faceto-face or via telephone with the 12 respondents accepting an invitation to participate. Compensation was not offered to respondents for their time. Interviews occurred in the US (Boston, JanuaryÁMarch 2009) and South Africa (Cape Town, Durban, and Johannesburg, FebruaryÁMarch 2009).
We developed an interview guide (Box A-1) to shape the interview process. In developing the guide, we began by reviewing the literature to identify a list of candidate programmatic characteristics of antiretroviral programs, including population health outcomes (Baltussen, 2006; Baltussen & Niessen, 2006; Baltussen, Stolk, Chisholm, & Aikins, 2006; Baltussen et al., 2007; Barron & Roma-Reardon, 2008; Bryan, Roberts, Heginbotham, & McCallum, 2002; Farrar, Ryan, Ross, & Ludbrook, 2000) , targeted vulnerable sub-group populations (Aikman, Unterhalter, & Boler, 2009; McCoy, 2003 Resource-Constrained Settings, 2005; McCoy, 2003; Rosen, Sanne, Collier, & Simon, 2005; Shaikh et al., 2006; Shisana et al., 2005) , and HIV program payment vehicles (Republic of South Africa National Treasury, 2007).
Bearing these characteristics in mind, we then outlined questions that would assist in obtaining further information regarding antiretroviral program priorities and the ethical considerations motivating those priorities.
Questions centered around how a respondent might think about setting priorities for antiretroviral provision, concerns for antiretroviral provision, points of conflict between or among different priorities that a respondent mentions, and the motivations underlying these responses. We also developed questions intended to provide contextual information regarding the respondent (e.g., the respondent's professional work and involvement in antiretroviral provision or scale-up), the history and current status of antiretroviral scale-up in South Africa, and the current and future status of financing for HIV treatment provision.
While the guide was designed mainly to capture respondents' key priorities and contextual information to interpret those priorities, in the guide's development, we outlined a series of follow-up probes. These probes were intended to obtain clarifying information about different ethical considerations and/or trade-offs. To generate the probes, we drew on an existing literature on rationing problems more generally (Daniels, 1994 (Daniels, , 2008 and as they related specifically to South Africa (e.g., gender (Aikman, Unterhalter, & Boler, 2009; McCoy, 2003 Resource-Constrained Settings, 2005; McCoy, 2003; Rosen, Sanne, Collier, & Simon, 2005; Shaikh et al., 2006; Shisana et al., 2005) disparities in antiretroviral access, as well as among other vulnerable groups (McCoy, 2003; Republic of South Africa Department of Health, 2007; South African National AIDS Council, 2007) ). Ultimately, the probes evaluated a number of different concerns that might underlie a respondent's treatment priorities, including those related to efficiency (e.g., best (population) health outcomes), equity (e.g., fair chances for different groups to receive treatment), and humanitarian rule of rescue (e.g., treating the sickest individuals first).
Five pre-test interviews were conducted to ensure that general concepts were included in the interview guide, to verify that questions and probes were understandable, and to assess question flow and focus . Pre-test subjects came from the settings described above, but due to logistical and financial constraints did not come from the same sample population as the respondents and were not directly involved in South Africa's HIV treatment scale-up efforts. However, we did make several important additions to the interview guide over the course of the pre-test interviews that facilitated more meaningful data collection during the formal interviews. First, we modified the guide to include additional contextual questions that would facilitate textual data interpretation within and across respondents. Second, we incorporated an explicit question on respondent motivations underlying their responses, since it was often difficult to infer them; this question was included to provide insight into any explicit ethical considerations the respondents might have. Third, we included an additional question on any conflicts a respondent might experience regarding his or her priorities for antiretroviral provision; posing this question allowed us to obtain information on the trade-offs a respondent might consider (e.g., efficiency concerns versus equity concerns) when reflecting on prioritization issues. Finally, we added a question on HIV treatment funding and financing designed to provide insight on the extent to which respondents believed South Africa's treatment program should be government versus donor funded.
After developing and pre-testing the interview guide, we conducted the interviews. In the interviews, the facilitator outlined the research question and the background motivating the question. The introduction was followed by a substantive interview, which included a preamble, main interview, and closing/debriefing (Frechtling & Sharp, 1997) .
The interviewer posed open-ended questions, which were intended to limit leading bias from the interviewer. Main questions were followed by semi-structured follow-up questions and probes. Given the complexity required to think through difficult resource allocation problems, main questions were necessarily iterative and relied on follow-up ''challenge'' questions (i.e., probes) as necessary and as time permitted to highlight conflicts arising out of the respondent's stated beliefs. This process assisted the respondent in beginning to identify a framework for making HIV treatment-related policy decisions, and it provided the interviewer with responses to the resource allocation problem under consideration.
Analysis
The textual data * including interview transcripts, field notes, and summaries * were assessed iteratively using a modified grounded theory approach , as outlined in the main text. Briefly, after reading the textual data for general impression, data were coded inductively by identified concepts/themes. Data were then organized by question to evaluate similarities and differences across respondents, as well as by individual to identify key concepts and themes. Finally, patterns within and across categories were identified and interpreted.
In this study, data consisted of interview transcripts, interview summaries, and memos. Codes, which are labels used to assign meaning to information collected during a study, were assigned to ''chunks'' of data . These chunks, which are the unit of analysis, typically consisted of multiple sentences and allowed for context-specific retrieval and organization of information. The smallest unit of analysis necessary to provide context to coded text was identified and ranged from a single phrase to multiple paragraphs. In the current study, broad coding categories were largely defined upon completion of data collection. After interview transcripts were reviewed for general impressions, a series of sub-categories and pre-liminary codes were defined. These codes were then refined iteratively throughout the coding process
The data were categorized in four main areas: 3 descriptive areas (Priorities, Funding, and Challenges & Constraints) and 1 interpretative area (Motivation) . ''Priorities'' were defined as explicit or implicit areas of major focus to improve antiretroviral therapy provision in South Africa; treatment priorities served as the main area of focus for the qualitative analysis. ''Funding'' (i.e., how antiretroviral therapy currently is financed and how it should be financed in the future) and ''Constraints'' (i.e., obstacles and barriers to providing antiretroviral therapy) were evaluated to provide context for the treatment priorities. Finally, ''Motivation'' (i.e., the reason(s) prompting the respondents' priorities for providing antiretroviral therapy) was evaluated to understand the rationale underlying respondent priorities. Within each of these main categories, sub-categories emerging from the data were identified and defined. Table A-1 lists the 48 distinct codes, which fall within a 60-code limit typically recommended for easy code retrieval and comprehension .
Supplementary Results

Considerations for antiretroviral provision Treatment priorities
Although not mentioned consistently across interviewees, respondents raised a multitude of other policy alternatives for consideration beyond those mentioned in the main text. These included increasing prevention efforts to reduce downstream treatment demand, improving HIV testing and linkage to care efforts as a means to increase treatment coverage, using activism and medical research to improve treatment coverage, raising social consciousness, intensifying private sector efforts to provide HIV treatment coverage to workers, and evaluating bigger picture, macro policies at the government level beyond health care to improve overall population health.
As a follow-up to discussion regarding treatment guidelines and clinical policy in South Africa, we also surveyed respondents regarding antiretroviral discontinuation after treatment failure, if antiretroviral therapy were not available to all HIV-infected South Africans and assuming that failed ART is only partially effective. In situations where the number of patients waiting for antiretroviral therapy exceeds South Africa's capacity to provide it, we found that nearly half (5/12) favored a policy in which antiretroviral therapy was discontinued among individuals having failed antiretroviral therapy in order to give fully effective antiretroviral therapy to treatment-naı¨ve individuals.
Underlying motivations and ethical considerations
In addition to the ethical considerations raised in the main text, we found that while some respondents appeared to support a particular ethical principle (e.g., maximizing health outcomes in the HIV-infected population), stated AIDS Care 787 underlying assumptions masked the degree to which respondent priorities reflected this principle. For example, when discussing prioritization of different clinical groups, some supported treatment of asymptomatic individuals ahead of symptomatic individuals due to perceptions of improved clinical outcomes (i.e., decreased morbidity and mortality, and therefore increased life expectancy) and decreased resource consumption compared to treatment of symptomatic individuals. These respondents believed that the short-term hospitalization costs associated with treating individuals with advanced disease outweighed long-term treatment costs associated with initiating individuals earlier in the course of the disease; thus, treating healthier patients, who would live longer, was cheaper. It is not only unclear whether this assumption actually holds true, but the assumption obscures the extent to which respondents might favor efficient, or health maximizing, outcomes. If the assumption is not true as recent data suggest (Walensky et al., 2009) , would some respondents still have prioritized healthier individuals over less healthy individuals? Obstacle to providing treatment is physical space/facilities. Funding
Obstacle to providing treatment is financial/money. Location
Obstacle to providing treatment is due to where (i.e., urban versus rural or high-versus lowburden areas) treatment is offered and sites are located. Delivery
Obstacle to providing treatment is where (e.g., hospital, primary care clinic, stand-alone HIV clinic) treatment is offered. Testing & linkage to care Obstacle to providing treatment is patient testing and linkage to care.
Indirect
Politics & policies Obstacle to providing treatment is political backing/support or current government policies directly or indirectly related to health. a Health system
Obstacle to providing treatment is the ability of the existing health system structure or infrastructure to support additional demand and services, lack of accreditation, or fragmentary nature of care provided.
Management
Obstacle to providing treatment is administrative, financial, programmatic, or political mismanagement.
HIV treatment guidelines
Obstacle to providing treatment is in the level of care/treatment provided as indicated by South African National Treatment Guidelines. b Education
Obstacle to providing treatment is not linking to care due to misinformation or lack of health education.
Data & IT
Obstacle to providing treatment is lack of information technology systems, technology-based infrastructure, and/or data collection efforts. Other
Other obstacle to providing treatment not listed above.
No Constraints Funding
Money is not considered an obstacle for providing treatment.
Other
Other examples in which respondent believes there are no constraints.
Conflicts
Internal disagreement or a discrepancy in the respondent's comments.
PRIORITIES Priorities
Patient level
Adherence Patient-level priority regarding level of patient adherence. First come, first served Patient-level priority regarding the order in which patients present. Orphan
Patient-level priority regarding child rearing responsibilities.
Sickness
Patient-level priority regarding how sick the patient is. Children
Patient-level priority regarding prioritizing children more generally or via pregnant women (via prevention of mother-to-child transmission). c System or population level Provider System-level priority regarding who (doctor, nurse) can offer treatment.
Integration
System-level priority regarding integration of HIV care with other diseases (e.g., TB). d Location System-level priority regarding where (i.e., urban versus rural or high-versus low-burden areas) treatment is offered and sites are located.
Politics & policies
System-level priority regarding removing policies prohibiting treatment access (e.g., nutritional and disability grants, which can keep individuals off treatment) or instituting policies that increase overall wellness.
Treatment guidelines
Programmatic prioritization based on number of ART regimens available, type of drugs, toxicity profile, etc. as outlined in South African national treatment guidelines.
AIDS Care 791 
Code Description
Delivery System-level priority regarding sites where (e.g., hospital, primary care clinic, stand-alone HIV clinic) treatment is offered. d Management System-level priority regarding improving administrative, financial, programmatic, or political management.
Coverage
Population-level priority regarding country-wide treatment coverage (ever-started, on-treatment, or lives saved). Attitude
Priority to change general attitude of how to provide treatment.
